🧬 CJC-1295 without DAC (Modified GRF 1-29) – Research Overview
0. Category:
Muscle Growth / Strength, Anti-Aging / Longevity, Fat Loss, Recovery & Repair
1. Primary Research Use:
CJC-1295 without DAC is primarily researched for its potential to stimulate the body’s natural production of growth hormone (GH), leading to increased levels of insulin-like growth factor 1 (IGF-1). This can result in enhanced muscle growth, improved fat metabolism, and accelerated recovery processes.
2. Simple Analogy:
Think of CJC-1295 without DAC as a “natural rhythm enhancer”—it amplifies the body’s own pulsatile release of growth hormone, akin to turning up the volume on your body’s natural growth signals without altering the tune.
3. What It Is (Chemical Summary):
CJC-1295 without DAC, also known as Modified GRF 1-29, is a synthetic analog of growth hormone-releasing hormone (GHRH). It consists of 29 amino acids and includes specific substitutions at positions 2, 8, 15, and 27 to increase stability and resistance to enzymatic degradation. Unlike its counterpart with DAC, this version lacks the Drug Affinity Complex, resulting in a shorter half-life.
4. Best Suited For:
This peptide is commonly researched by those interested in:
- Enhancing muscle mass and strength.
- Reducing body fat.
- Improving recovery times from injuries or intense training.
- Exploring anti-aging therapies.
5. Not Recommended For / Caution In Research With:
Caution is advised when researching CJC-1295 without DAC in individuals with:
- Active cancer, due to potential stimulation of cell proliferation.
- Diabetes or insulin resistance, as GH can affect glucose metabolism.
- Pregnancy or breastfeeding, due to insufficient safety data.
6. Synergistic Peptide Stacks:
CJC-1295 without DAC is often studied in combination with:
- Ipamorelin: A growth hormone secretagogue that, when combined, may amplify GH release.
- GHRP-6 or GHRP-2: Other secretagogues that can synergize with CJC-1295 to enhance GH pulsatility.
7. Common Dosing Guidelines (Research Use):
| Experience Level | Dosage | Frequency |
|---|---|---|
| Beginner | 100 mcg | 1–2 times daily |
| Intermediate | 100–200 mcg | 2–3 times daily |
| Advanced | 200–300 mcg | 2–3 times daily |
Note: Administration is typically via subcutaneous injection.
8. Cycling Information:
Research protocols often involve continuous administration for 8–12 weeks, followed by a 2–4 week break. This cycling aims to assess efficacy and monitor for any potential desensitization or side effects.
9. Similar Peptides & Comparison Chart:
| Peptide | Half-Life | Mechanism of Action | Dosing Frequency | Notes |
|---|---|---|---|---|
| CJC-1295 (No DAC) | ~30 minutes | Mimics natural GHRH, short-acting | Multiple times daily | Promotes pulsatile GH release |
| CJC-1295 (With DAC) | ~6–8 days | Extended GHRH analog, long-acting | Once or twice weekly | Provides sustained GH release |
| Sermorelin | ~10–20 minutes | GHRH analog, short-acting | Multiple times daily | Similar to CJC-1295 No DAC in action |
10. Method of Administration:
CJC-1295 without DAC is administered via subcutaneous injection, typically in the abdominal area or thigh, using sterile techniques to ensure safety and efficacy.
11. Regulatory Status (FDA Approval):
CJC-1295 without DAC is not approved by the FDA for any medical or veterinary use. It is classified as an investigational compound and is available for research purposes only.
12. Legal Disclaimer:
All products discussed are intended for laboratory, scientific, and research purposes only. These products are not approved by the FDA for human or veterinary use and are not intended to diagnose, treat, cure, or prevent any disease. They must not be used for any form of medical application or personal use.
The information presented is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before making decisions regarding your health.
By accessing or purchasing these materials, you affirm that you are a qualified researcher or are acting under the supervision of one. All sales are final.
Reviews
There are no reviews yet.